(NASDAQ: CDXS) Codexis's forecast annual revenue growth rate of 22.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.33%.
Codexis's revenue in 2025 is $57,164,000.On average, 9 Wall Street analysts forecast CDXS's revenue for 2025 to be $6,046,656,344, with the lowest CDXS revenue forecast at $5,555,420,804, and the highest CDXS revenue forecast at $6,416,662,678. On average, 8 Wall Street analysts forecast CDXS's revenue for 2026 to be $7,355,083,234, with the lowest CDXS revenue forecast at $6,678,709,126, and the highest CDXS revenue forecast at $8,302,801,339.
In 2027, CDXS is forecast to generate $9,636,954,457 in revenue, with the lowest revenue forecast at $7,855,435,787 and the highest revenue forecast at $12,290,817,898.